Turinabol 10 – Hilma Biocare

Description

DATA SHEET

MORE INFO

Information on Turninabol (Tbol)
Hilma Biocare Turinabol 10mg is a potent derivative of dianabol. This oral steroid is structurally a cross between methandrostenolone and clostebol (4-cholorotestosterone)
It has the same base structure as Dianabol with the added 4-chloro alteration of clostebol. In essence it’s a cousin of Dianabol displaying no estrogenic and less androgenic activity that Dianabol.
Turinabol you will get good hard gains and also does not create risk for estrogenic side effects, so there is limited water retention or risk for gynecomastia.
In studies done on male athletes that were given 10 mg every day over six weeks, no negative health effects or side effects were reported.
It is also used in low doses to reduce the binding of SHBG to other steroids. Oral Turinabol has the ability to reduce SHBG and allow testosterone to be more readily used.
Recently, Turinabol has found its way back into the hands of athletes all over the world. Turinabol became a steroid of infamy during the 1990’s when it was revealed that it had been one of the closely held secrets inside the “East German Doping Machine” This is referring to the state-sponsored doping program called “State Plan Research Theme 14.25” that operated in East Germany between 1974 and 1989 that had one goal – to cheat the Olympics
Jenapharm discontinued Turinabol in 1994 however Lixus has recreated the chemical structure.
Most users do fairly well with doses between 40 and 60 milligrams per day, taken in divided doses.
Turinabol tubs contains 60 tablets 10mg Chlorodehydromethyltestosteron
Activity
Androgenic: 38
Anabolic: 200
Estrogenic: None
Progestational: Low
Active Half life
16 hours
HILMA BIOCARE TURINABOL is a 17-alpha alkylated anabolic steroid for oral use. It promotes anabolism through androgen receptor activity and is strongly anabolic and moderately androgenic. When taken in clinical doses, it produces potent increases in strength and moderate increases in muscle mass. In short term clinical trials, it has been well tolerated in healthy male subjects during 6 weeks of treatment